VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS

EHA Library, Sai Prasad Desikan, 357625

RESPONSE AND SURVIVAL OUTCOMES WITH HYPOMETHYLATING AGENTS IN AN ARGENTINEAN COHORT OF 113 PATIENTS WITH CHRONIC MYELOMONOCITIC LEUKEMIA

EHA Library, Jacqueline Gonzalez, 357626

UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)

EHA Library, Courtney DiNardo, 357627

CLINICAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED ANALYSIS

EHA Library, Amer M. Zeidan, 357628

CLINICAL APPLICABILITY OF TARGETED NEXT-GENERATION SEQUENCING FOR PRECISION MEDICINE IN DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Dehong Huang, 358032

THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19 CAR-T CELLS.

EHA Library, Anna Dodero, 358033

REAL LIFE OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTRE EXPERIENCE

EHA Library, Irene Dogliotti, 358034

RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY

EHA Library, Jeanette Doorduijn, 358035

BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY

EHA Library, Nancy L. Bartlett, 358037

EFFECTIVENESS OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS STRATEGIES IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Tayfur Toptas, 358038

ARE EXTRANODAL LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA MORE AGRESSIVE THAN NODAL FORMS?

EHA Library, Catarina Fernandes, 358039

REAL-WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA POST CAR-T FAILURE

EHA Library, Carlos Flores Avile, 358040

REAL-WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WHO RECEIVED CAR-T THERAPY

EHA Library, Carlos Flores Avile, 358041

CAR-T MORPHOLOGICAL CHARACTERISTICS AND DYNAMICS IN PERIPHERAL BLOOD, EVALUATED BY A NOVEL MICROSCOPY PLATFORM

EHA Library, Gil Fridberg, 358042

PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT

EHA Library, Peter Borchmann, 358043

ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.

EHA Library, Caixia Li, 358044

A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE

EHA Library, Herve Ghesquieres, 358045

END OF TREATMENT 18F FDG-PET/CT RESPONSE IS PROGNOSTIC FOR OVERALL AND PROGRESSION-FREE SURVIVAL IN PERIPHERAL T-CELL LYMPHOMA: RESULTS OF THE UK NCRI PHASE 2 RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY

EHA Library, Mary Gleeson, 358046

PERSONALIZED TREATMENT ACCORDING TO BIOLOGICAL PROFILE IMPROVES OUTCOME OF NEWLY DIAGNOSED PATIENTS AFFECTED BY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE EXPERIENCE

EHA Library, Anna Guidetti, 358047

OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL

EHA Library, Franck Morschhauser, 358048

INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Andrew McMillan, 358049

ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL

EHA Library, Yuqin Song, 358050

ANALYSIS OF PERIPHERAL NEUROPATHY USING CLINICIAN- AND PATIENT-REPORTED OUTCOMES IN THE POLARIX STUDY

EHA Library, Marek Trneny, 358051

A POPULATION PHARMACOKINETIC MODEL OF HIGH-DOSE METHOTREXATE IN ADULTS WITH CANCER IDENTIFIES BASELINE ALBUMIN, BODY WEIGHT, AND TIME-DEPENDENT CREATININE AS PREDICTORS OF ACUTE KIDNEY INJURY

EHA Library, Scott Howard, 358052

A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)

EHA Library, Tapan Kadia, 358053

A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.

EHA Library, Matko Kalac, 358054

ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING SECOND-LINE AXICABTAGENE CILOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Pier Luigi Zinzani, 358056

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY

EHA Library, Paolo Strati, 358057

MACHINE-LEARNING ALGORITHM TO DETECTION OF LYMPHOMA WITH BONE MARROW INVOLVEMENT VIA FDG-18 PET/CT

EHA Library, Cho-Hao Lee, 358058

RELAPSE AND OCCURRENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RITUXIMAB ERA, A NATIONWIDE OBSERVATIONAL STUDY

EHA Library, Hyun Jung Lee, 358059

ZANUBRUTINIB PLUS RCHOP(ZR-CHOP) REGIMEN ACHIEVES HIGH COMPLETE RESPONSE RATE IN THE TREATMENT OF NEWLY-DIAGNOSED DOUBLE-EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Zengjun Li, 358060

INTENDED USE OF GLUCARPIDASE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND IMPAIRED RENAL FUNCTION – THE VALIDATE STUDY

EHA Library, Sven Liebig, 358061

THE OPTIMIZED HLH INFLAMMATORY (OHI) INDEX IDENTIFIES LYMPHOMA PATIENTS WITH UNEXPECTEDLY HIGH MORTALITY NOT RELATED TO DISEASE PROGRESSION

EHA Library, Adi Zoref-Lorenz, 358062

TREATMENT PATTERNS AND REAL-WORLD OUTCOMES IN PATIENTS (PT) WITH LARGE B-CELL LYMPHOMA (LBCL) WHO RECEIVED SECOND-LINE (2L) THERAPY

EHA Library, Matthew Lunning, 358063

GASTROINTESTINAL BLEEDING SIGNIFICANTLY REDUCED THE EFFICACY AND SURVIVAL OF CD19 CAR-T CELL THERAPY IN PATIENTS WITH GASTROINTESTINAL TRACT INVOLVEMENT OF REFRACTORY/RELAPSED B-CELL LYMPHOMA

EHA Library, Kai Hu, 358064

PROGNOSTIC ROLE OF TUMOR P53 MUTATION IN DIFFUSE LARGE B CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Ji Ma, 358065

CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REPORT FROM THE PROSPECTIVE INTERNATIONAL T-CELL LYMPHOMA PROJECT

EHA Library, Carlos Sergio Chiattone, 358067

INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS

EHA Library, Frederik O. Meeuwes, 358068

IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARKER FINDINGS FROM A PIVOTAL PHASE II EXPANSION STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Emily C. Piccione, 358069

PERSONALIZED TREATMENT FOR ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Hironao Nukariya, 358071

PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

EHA Library, Raul Cordoba, 358072

SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE

EHA Library, Michael Roost Clausen, 358073

SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

EHA Library, Björn E. Wahlin, 358074

ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA

EHA Library, Kexing Ren, 358075

INTRATHECAL METHOTREXATE PROPHYLAXIS AND CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH INTENSIFIED R-ACVBP STRATEGY

EHA Library, Loïc Renaud, 358076

FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA

EHA Library, Xinfeng Chen, 358077

ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Huayuan Zhu, 358078

CHARACTERISTICS OF SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA – A SUPPLEMENTARY ANALYSIS OF JCOG0601

EHA Library, Kazuyuki Shimada, 358079

DIFFUSE LARGE B-CELL LYMPHOMA RICHTER SYNDROME IN CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE ANALYSIS OF TREATMENT OUTCOMES IN POLISH ADULT LEUKEMIA STUDY GROUP

EHA Library, Oktawia Sośnia, 358080

PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS

EHA Library, Raphael Steiner, 358081

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE）

EHA Library, Youhong Tang, 358082

EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS

EHA Library, Amal Haujir, 358083

SECONDARY PRIMARY MALIGNANCIES (SPM) AFTER HIGH-DOSE CHEMOTHERAPY (HDT) WITH AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR LYMPHOMA: A DANISH NATIONWIDE COHORT STUDY

EHA Library, Trine Trab, 358084

A RETROSPECTIVE REVIEW OF SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS FROM A TEACHING HOSPITAL IN SINGAPORE.

EHA Library, Allison Ching Yee, 358085

POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY

EHA Library, Bahar Uncu Ulu, 358086

INCIDENCE AND RISK FACTORS FOR CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA

EHA Library, Theodoros Vassilakopoulos, 358087

RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES

EHA Library, Theodoros Vassilakopoulos, 358088

PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS

EHA Library, Theodoros Vassilakopoulos, 358089

ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE

EHA Library, Michael L. Wang, 358090

PRINCIPLES OF PRECISION ONCOLOGY IN PRIMARY REFRACTORY HIGH-GRADE B-CELL LYMPHOMA WITH MYC-, BCL2 AND/OR BCL6 REARRANGEMENTS (HGBL-DH/TH)

EHA Library, Hanno Witte, 358091

PRIMARY REFRACTORY PLASMABLASTIC LYMPHOMA: A PRECISION ONCOLOGY APPROACH

EHA Library, Hanno Witte, 358092

REAL-WORLD EXPERIENCE OF OUTCOMES WITH GLOFITAMAB SALVAGE THERAPY FOR RELAPSE/REFRACTORY B-CELL LYMPHOMA IN TAIWAN: MINIMAL SAFETY CONCERN WITH HEPATITIS B REACTIVATION

EHA Library, Shang-Ju Wu, 358093

GENOTYPING ON CIRCULATING TUMOR DNA IMPROVES MUTATION DETECTION RATE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Wei Xu, 358094

EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA

EHA Library, Kai Hu, 358095

PRELIMINARY RESULTS OF A PHASE Ⅱ STUDY OF ZANUBRUTINIB COMBINED WITH IMMUNOCHEMOTHERAPY IN PATIENTS WITH CD79A/CD79B-MUTANT DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Zhihua Yao, 358096

EFFICACY ANALYSIS OF PEGASPARGASE, GEMCITABINE, OXALIPLATIN, DEXAMETHASONE COMBINED WITH TISLELIZUMAB IN FIRST-LINE TREATMENT OF PLASMA EBV-DNA POSITIVE EXTRANODAL NK/T CELL LYMPHOMA

EHA Library, Zunmin Zhu, 358097

TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY

EHA Library, Emmanuel Bachy, 358098

THE INCIDENCE AND SURVIVAL OUTCOMES OF PATIENTS WITH PRIMARY GASTRIC T-CELL LYMPHOMA: A SEER POPULATION-BASED STUDY

EHA Library, Minyue Zhang, 358099

ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL

EHA Library, Lei Zhang, 358100

ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY

EHA Library, Yan Zhang, 358101

RUXOLITINIB COMBINED WITH DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INTERIM ANALYSIS OF A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE 2 CLINICAL TRIAL

EHA Library, De Zhou, 358102

ROLE OF SELECT T HELPER CELL MONONUCLEAR CELL SUBSETS PROMOTING EPSTEIN-BARR VIRUS-DRIVEN LYMPHOPROLIFERATIVE DISEASE IN THE HU-PBL-SCID MODEL

EHA Library, Elshafa Hassan Ahmed, 358103

CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.

EHA Library, elisa genuardi, 358104

DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA

EHA Library, Pilar Andersen, 358105

GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES

EHA Library, Isharat Yusuf, 358106

CTP SYNTHASE 1 IS A NOVEL TARGET IN T CELL CANCERS, WITH SMALL MOLECULE INHIBITION INDUCING DEATH OF NEOPLASTIC HUMAN T CELLS IN VITRO AND INHIBITION OF THEIR GROWTH IN AN IN VIVO XENOTRANSPLANT MODEL

EHA Library, Philip Beer, 358107

INHIBITION OF THE PENTOSE-PHOSPHATE-PATHWAY (PPP) MEDIATES MACROPHAGE REPROGRAMMING FROM SUPPORTIVE BYSTANDER FUNCTION TOWARDS ANTIBODY-DEPENDENT LYMPHOMA CELL CLEARANCE AND LYMPHOMA SUPPRESSION

EHA Library, Anna Beielstein, 358108

EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA

EHA Library, Fiona Brown, 358109

BONE-BASED 3D SCAFFOLD AS AN IN-VITRO MODEL OF MICROENVIRONMENT-LYMPHOMA INTERACTION

EHA Library, Jessica Ceccato, 358110

PREDICTING THE RESPONSE OF DLBCL CELLS TO BH3-MIMETICS USING SYSTEMS BIOLOGY

EHA Library, Simon Mitchell, 358111

MAVORIXAFOR DISRUPTS THE CROSS TALK BETWEEN WALDENSTRÖM'S MACROGLOBULINEMIA CELLS AND THE BONE MARROW MICROENVIRONMENT RESULTING IN ENHANCED SENSITIVITY TO B-CELL TARGETED THERAPIES

EHA Library, Halenya Monticelli, 358112

RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS

EHA Library, Vera de Jonge, 358113

TUMOR-ASSOCIATED MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS IS A POTENTIAL PROGNOSTIC BIOMARKER, PROMOTING MULTI-DRUG RESISTANCE IN NHL PATIENTS BY MODULATING IL-6/IL-10/IL-1Β AXIS

EHA Library, Sukanya Dhar, 358114

A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY

EHA Library, Daniela Drandi, 358115

MOLECULAR CHARACTERIZATION AND CLONAL EVOLUTION OF MYCOSIS FUNGOIDES

EHA Library, Léa Fléchon, 358116

MOLECULAR CYTOGENETICS CHARACTERIZATION OF CLASSICAL HODGKIN LYMPHOMA. ROL OF 9P24.1 (PD-L1/PD-L2) POLYSOMIES

EHA Library, Mauro García-Montenegro, 358117

CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA

EHA Library, Agnete Granau, 358118

UNRAVELING THE GENETICS OF TRANSFORMED SPLENIC MARGINAL ZONE LYMPHOMA

EHA Library, Marta Grau, 358119

ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL

EHA Library, Gareth Gregory, 358120

EZH2 INHIBITORS MEDIATE PLATINUM RESISTANCE BY ENHANCED EFFLUX

EHA Library, Elisabeth Groß, 358121

A SENSITIVE NGS ASSAY TO DETECT MEASURABLE RESIDUAL DISEASE (MRD) IN B-CELL LYMPHOPROLIFERATIVE DISEASES

EHA Library, Presha Shah, 358122

HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY

EHA Library, Simon Husby, 358123

TMEM244 GENE EXPRESSION AS A POTENTIAL BLOOD DIAGNOSTIC MARKER THAT CAN DISTINGUISH SÉZARY SYNDROME FROM MYCOSIS FUNGOIDES AND BENIGN ERYTHRODERMA

EHA Library, Katarzyna Iżykowska, 358124

FLOW CYTOMETRY COMBINED WITH SYSTEMS BIOLOGY ENABLES RATIONAL TARGETING OF NFKB IN DLBCL

EHA Library, Eleanor JAYAWANT, 358125

HSP110 FAVORS BCR SIGNALING THROUGH SYK PHOSPHORYLATION IN DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Vincent Cabaud Gibouin, 358126

DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).

EHA Library, Yanrong Jiang, 358127

VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA

EHA Library, Melanie Frigault, 358128

IMMUNE REGULATORY CELLS IN B-CELL LYMPHOMAS: SIGNIFICANT HETEROGENEITY ACROSS HISTOLOGIC TYPES.

EHA Library, Christina Kalpadakis, 358129

ELUCIDATING TUMOR SUPPRESSOR FUNCTIONS OF TET2 IN B CELL LYMPHOMAS

EHA Library, Nadine Kinz, 358130

GP130/STAT3 AXIS IS A POTENTIAL THERAPEUTIC TARGET FOR HISTONE DEACETYLASE INHIBITOR-RESISTANT CUTANEOUS T-CELL LYMPHOMA

EHA Library, Yuto Takahashi, 358131